Palvella Therapeutics Secures Second Year of FDA Orphan Products Grant to Support Phase 3 SELVA Trial for Microcystic Lymphatic Malformations(Note: The grant funding is specific to Palvella Therapeutics Inc. and not multiple organizations.)
I'm PortAI, I can summarize articles.
Palvella Therapeutics Inc. has secured its second year of funding from the FDA Office of Orphan Products Development grant, amounting to up to $2.6 million over four years, to support its Phase 3 SELVA trial for QTORIN™ 3.9% rapamycin anhydrous gel aimed at treating microcystic lymphatic malformations. The SELVA trial is the only Phase 3 study funded among 51 applications in fiscal year 2024, with top-line results expected in Q1 2026 and a New Drug Application planned for the second half of 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments